Renal Arteriosclerosis Develops Prematurely in Lupus Nephritis
A study found that renal arteriosclerosis develops 2 decades earlier in patients with lupus nephritis compared with healthy age-matched controls.
Lupus Nephritis
Belimumab Associated With Meaningful Improvement in Lupus Nephritis Trial
GlaxoSmithKline announced positive results from the phase 3 BLISS-LN trial of belimumab for the treatment of active lupus nephritis in adult patients.
Itolizumab Receives Fast Track Status for Lupus Nephritis
The FDA has granted Fast Track designation for itolizumab (EQ001; Equillium) for the treatment of lupus nephritis.
Voclosporin Superior to Standard of Care in Lupus Nephritis Trial
Voclosporin was found to be superior to standard-of-care treatment in patients with lupus nephritis, according to data from the phase 3 AURORA trial.
Obinutuzumab Gets Breakthrough Status for Treatment of Lupus Nephritis
The FDA has granted Breakthrough Therapy designation to obinutuzumab (Genentech), a CD20-directed cytolytic antibody, for the treatment of adults with lupus nephritis.
Biopsy-Informed Management Safely, Accurately Predicts Flares in Lupus Nephritis
This study reports the long-term renal outcomes of kidney biopsies performed at prespecified intervals to determine the safety and accuracy of tapering of maintenance immunosuppression.
Elevated Fracture Risk Observed in SLE, Lupus Nephritis
Patients with systemic lupus erythematosus were at greater risk for fractures compared with controls.
Case Study: Systemic Lupus Erythematosus With Lupus Nephritis and Thrombotic Microangiopathy
A 19-year-old woman presents with complaints of progressive shortness of breath, chest pain, and lower extremity edema over the past month.
Lupus Nephritis Therapy Response Predicts Survival Odds
Complete response to induction therapy is associated with significant 82% decreased odds of death at 12 months.
Kidney Transplantation Increases Survival in Lupus Nephritis Cases
In a nationwide study, renal transplant recipients with lupus nephritis had a 70% lower risk for all-cause mortality than nonrecipients.
Next post in Systemic Lupus Erythematosus
